STOCK TITAN

ProMIS Neurosciences (PMN) S-3 Filings

PMN NASDAQ

Here are the S-3 shelf registrations from ProMIS Neurosciences Inc. (PMN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow PMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMN filings page.

Rhea-AI Summary

ProMIS Neurosciences filed a shelf registration and prospectus supplement to offer up to $50,000,000 of common shares under an at-the-market sales agreement.

The registration statement also covers up to $200,000,000 of securities in aggregate. Sales under the Sales Agreement with H.C. Wainwright & Co. LLC may be made from time to time on Nasdaq or otherwise, and Wainwright may receive commissions up to 3.0% of gross sales. The prospectus supplement states the company may use net proceeds to advance clinical development of PMN310, for working capital and general corporate purposes. The offering is subject to market conditions and completion of sales; timing and amounts sold will be determined by market conditions and the Sales Agreement.

Rhea-AI Summary

ProMIS Neurosciences Inc. files a Form S-3 to register 13,830,592 Common Shares for resale by certain purchasers from a January 29, 2026 private placement.

The registration covers (i) 6,815,296 Common Shares sold in the private placement, (ii) 6,915,296 Common Shares issuable upon exercise of Common Share Warrants, and (iii) 100,000 Common Shares issuable upon exercise of Pre-Funded Warrants. The company will not receive proceeds from resale by the Selling Securityholders, though it will receive proceeds from any warrant exercises for cash.